Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition
- PMID: 31700989
- PMCID: PMC6827361
- DOI: 10.1016/j.dadm.2019.08.008
Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition
Abstract
Introduction: Neuroaxonal damage may contribute to cognitive changes preceding clinical dementia. Accessible biomarkers are critical for detecting such damage.
Methods: Plasma and cerebrospinal fluid (CSF) neurofilament light (NFL) were related to neuropsychological performance among Vanderbilt Memory & Aging Project participants (plasma n = 333, 73 ± 7 years; CSF n = 149, 72 ± 6 years) ranging from normal cognition (NC) to mild cognitive impairment (MCI). Models adjusted for age, sex, race/ethnicity, education, apolipoprotein E ε4 carriership, and Framingham Stroke Risk Profile.
Results: Plasma NFL was related to all domains (P values ≤ .008) except processing speed (P values ≥ .09). CSF NFL was related to memory and language (P values ≤ .04). Interactions with cognitive diagnosis revealed widespread plasma associations, particularly in MCI participants, which were further supported in head-to-head comparison models.
Discussion: Plasma and CSF NFL (reflecting neuroaxonal injury) relate to cognition among non-demented older adults albeit with small to medium effects. Plasma NFL shows particular promise as an accessible biomarker with relevance to cognition in MCI.
Keywords: Alzheimer's disease; Cerebrospinal fluid; Cognition; Mild cognitive impairment; Neurofilament light; Plasma.
© 2019 The Authors.
Figures
References
-
- Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005;233:183–198. - PubMed
-
- Skillback T., Farahmand B., Bartlett J.W., Rosen C., Mattsson N., Nagga K. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology. 2014;83:1945–1953. - PubMed
-
- Bacioglu M., Maia L.F., Preische O., Schelle J., Apel A., Kaeser S.A. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron. 2016;91:494–496. - PubMed
Grants and funding
- UL1 TR000445/TR/NCATS NIH HHS/United States
- R01 AG056534/AG/NIA NIH HHS/United States
- U54 HD083211/HD/NICHD NIH HHS/United States
- R01 AG059716/AG/NIA NIH HHS/United States
- T32 GM007347/GM/NIGMS NIH HHS/United States
- T32 GM152284/GM/NIGMS NIH HHS/United States
- K01 AG049164/AG/NIA NIH HHS/United States
- K24 AG046373/AG/NIA NIH HHS/United States
- R01 NS100980/NS/NINDS NIH HHS/United States
- T32 AG058524/AG/NIA NIH HHS/United States
- R01 AG034962/AG/NIA NIH HHS/United States
- K23 AG048347/AG/NIA NIH HHS/United States
- F32 AG058395/AG/NIA NIH HHS/United States
- K23 AG045966/AG/NIA NIH HHS/United States
- S10 OD023680/OD/NIH HHS/United States
LinkOut - more resources
Full Text Sources